Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

SUMMIT TECHNOLOGIES' EXCIMER LASER PROMOTIONAL VIOLATIONS

This article was originally published in The Gray Sheet

  • News

Executive Summary

SUMMIT TECHNOLOGIES' EXCIMER LASER PROMOTIONAL VIOLATIONS alleged by FDA in an Oct. 27 warning letter to the company. The warning letter cites three violative situations regarding promotion of the excimer laser, one involving the sale of the device. The laser has not yet been approved by FDA, but the agency's Ophthalmic Devices Panel has recommended approval for both photorefractive keratectomy ("The Gray Sheet" Oct. 24, p. 3) and phototherapeutic keratectomy ("The Gray Sheet" March 28, p. 13).

Table

View full table

Tags:
Latest Headlines

Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold

It’s Official: FDA Drops Final Rule On LDTs

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

See All
UsernamePublicRestriction

Register

MT003081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By